Stifel Nicolaus Has Lowered Expectations for Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price

Bolt Biotherapeutics (NASDAQ:BOLT) had its price objective lowered by stock analysts at Stifel Nicolaus from $1.50 to $1.25 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 184.09% from the company’s current price.

Bolt Biotherapeutics Trading Up 4.8 %

Shares of Bolt Biotherapeutics stock opened at $0.44 on Tuesday. Bolt Biotherapeutics has a 1 year low of $0.38 and a 1 year high of $1.56. The company’s fifty day simple moving average is $0.47 and its 200-day simple moving average is $0.56. The company has a market cap of $16.84 million, a price-to-earnings ratio of -0.26 and a beta of 0.94. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.38). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. As a group, sell-side analysts expect that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Institutional Trading of Bolt Biotherapeutics

A number of hedge funds have recently modified their holdings of BOLT. FMR LLC increased its position in shares of Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the period. Citadel Advisors LLC acquired a new stake in Bolt Biotherapeutics during the fourth quarter worth $42,000. Velan Capital Investment Management LP bought a new stake in Bolt Biotherapeutics in the 4th quarter valued at $27,000. Squarepoint Ops LLC acquired a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at $26,000. Finally, Millennium Management LLC bought a new position in shares of Bolt Biotherapeutics during the 4th quarter worth about $25,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.